340B

Oct 31, 2018
The Department of Health and Human Services today proposed implementing on Jan. 1 its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers.
Sep 18, 2018
Leaders from the AHA and individual 340B hospitals today came together to announce new principles for ensuring good stewardship of the 340B program. The new AHA-led initiative seeks to strengthen the 340B program by increasing transparency while helping 340B hospitals better publicly communicate…
May 17, 2021
AHA statement on HRSA ordering drug companies to restore 340B discounts on drugs dispensed at community pharmacies
May 17, 2021
The AHA expresses support for legislation  H.R. 3203 introduced in the House that would provide certainty to hospitals participating in the 340B Drug Pricing Program during the COVID-19 public health emergency.
May 5, 2021
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ASTRAZENECA PHARMACEUTICALS LP, Plaintiff, v. XAVIER BECCERA, et al., Defendants. CASE NO.: 1:21-CV-00027-LPS
May 5, 2021
American Hospital Association, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, National Association of Children’s Hospitals d/b/a Children’s Hospital Association, and American Society of Health-System Pharmacists, by and through their undersigned attorneys,…
Apr 20, 2021
The AHA and five other health care organizations today sent a letter to Health and Human Services Secretary Xavier Becerra urging him to stop the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income and rural…
Apr 20, 2021
The leaders of six major organizations representing hospitals and pharmacists sent a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra urging him to halt the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large…
Apr 20, 2021
The AHA and five other health care organizations sent the attached letter to HHS Secretary Becerra urging him to stop the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income and rural Americans.